SELLAS Life Sciences (SLS) Non Operating Income (2012 - 2026)
SELLAS Life Sciences' (SLS) quarterly Non Operating Income came in at $845000.0 in Q1 2026, up 238.0% year-on-year from $250000.0 in Q1 2025, and up 41.54% on a QoQ basis from $597000.0 in Q4 2025.
SELLAS Life Sciences (SLS) Non Operating Income (2012 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has 11 years of Non Operating Income data on file, last reported at $845000.0 in Q1 2026.
- On a quarterly basis, Non Operating Income rose 238.0% year-over-year to $845000.0 in Q1 2026; TTM through Mar 2026 was $2.0 million, a 149.81% increase from a year earlier, with the FY2025 full-year figure at $1.4 million, up 123.26% from the prior year.
- Non Operating Income for Q1 2026 stood at $845000.0, up from $597000.0 in the prior quarter.
- Over the last five years, Non Operating Income for SLS reached as high as $845000.0 in Q1 2026 and fell as low as $37000.0 in Q4 2023.
- Historically, Non Operating Income has averaged $254437.5 across 5 years, with a median of $209500.0 in 2022.
- Across the five-year window, Non Operating Income slumped 88.62% in 2023 and jumped 389.19% in 2024, its largest moves.
- Year by year, Non Operating Income stood at $325000.0 in 2022, then slumped by 88.62% to $37000.0 in 2023, then soared by 389.19% to $181000.0 in 2024, then soared by 229.83% to $597000.0 in 2025, then soared by 41.54% to $845000.0 in 2026.
- Per Business Quant data, the three most recent Non Operating Income figures were $845000.0 in Q1 2026, $597000.0 in Q4 2025, and $292000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -9.22 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 444,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 188.30 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 5.75 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -8.59 Mn |
| 10 | SELLAS Life Sciences | 1.96 Bn | 1.96 Bn | - | 845,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 845,000.00 |
| Dec 31, 2025 | 597,000.00 |
| Sep 30, 2025 | 292,000.00 |
| Jun 30, 2025 | 272,000.00 |
| Mar 31, 2025 | 250,000.00 |
| Dec 31, 2024 | 181,000.00 |
| Sep 30, 2024 | 221,000.00 |
| Jun 30, 2024 | 151,000.00 |
| Mar 31, 2024 | 79,000.00 |
| Dec 31, 2023 | 37,000.00 |
| Sep 30, 2023 | 94,000.00 |
| Jun 30, 2023 | 210,000.00 |
| Mar 31, 2023 | 184,000.00 |
| Dec 31, 2022 | 325,000.00 |
| Sep 30, 2022 | 124,000.00 |
| Jun 30, 2022 | 209,000.00 |
| Dec 31, 2019 | -7.50 Mn |
| Sep 30, 2019 | -4.20 Mn |
| Jun 30, 2019 | -3.13 Mn |
| Dec 31, 2018 | -14.86 Mn |